AZD8329 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that regulates the conversion of inactive cortisone to active cortisol in key tissues such as liver, adipose, and muscle. It is primarily researched for its therapeutic potential in metabolic disorders, including type 2 diabetes and obesity, by locally reducing glucocorticoid activity to improve insulin sensitivity, glucose homeostasis, and lipid metabolism. Additionally, its mechanism supports applications in cardiovascular diseases, such as hypertension and heart failure, through blood pressure reduction, enhanced vascular function, and decreased cardiac workload, as demonstrated in preclinical models. Ongoing clinical and preclinical studies continue to assess its safety, efficacy, and viability as a novel treatment in metabolic and cardiovascular medicine.